Neumora Therapeutics, Inc.
Company Stats
- Market Cap
- $112.0M
- as of Sep 30, 2026
- Enterprise Value
- -$10.3M
- Shares Outstanding
- 187.9M
- Free Float
- 29.7%
Income Statement
- Operating Income
- -$241.2M
- Net Income
- -$236.9M
- EBITDA
- -$240.9M
- Non-cash Impairment
- $595,000
Balance Sheet
- Cash & Equivalents
- $182.5M
- Total Debt
- $60.2M
- Net Cash
- $122.3M
Returns & Capital
- SBC, 3Y Avg
- $29.0M
Cash Flow by Year
| Year | Revenue | FCF | Margin |
|---|---|---|---|
| FY2023 | — | -$163.4M | — |
| FY2022 | — | -$115.4M | — |
Annual filing data through FY ended December 31, 2025; shares and float as of October 15, 2026. Yields and enterprise value use the calculated market cap above, at its as-of date. Ratios are our calculations from reported figures.
Stronger demand supports expansion as pricing diverges